Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Mirikizumab Promising for Plaque Psoriasis

  |  

References

  1. Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate to severe plaque psoriasis: Results from a randomized phase 2 study. Br J Dermatol. 2019 Feb 7. doi: 10.1111/bjd.17628. [Epub ahead of print]
  2. Eli Lilly & Company. A study of mirikizumab (LY3074828) in participants with moderate to severe plaque psoriasis. ClinicalTrials.gov. 2018 Dec 4.
  3. National Psoriasis Foundation. Mirikizumab (LY3074828). 2019 Mar 19.

Related Articles
    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…